Log in

NASDAQ:PLXP - PLx Pharma Stock Price, Forecast & News

+0.02 (+0.36 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: $5.63
50-Day Range
MA: $5.05
52-Week Range
Now: $5.63
Volume931 shs
Average Volume4,608 shs
Market Capitalization$51.51 million
P/E RatioN/A
Dividend YieldN/A
PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PLXP



Sales & Book Value

Annual Sales$750,000.00
Book Value$0.74 per share


Net Income$900,000.00
Net Margins-1,911.69%


Market Cap$51.51 million
Next Earnings Date3/13/2020 (Estimated)
OptionableNot Optionable

Receive PLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for PLXP and its competitors with MarketBeat's FREE daily newsletter.

PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc (NASDAQ:PLXP) issued its quarterly earnings data on Friday, November, 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.04. The biotechnology company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.18 million. View PLx Pharma's Earnings History.

When is PLx Pharma's next earnings date?

PLx Pharma is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for PLx Pharma.

What is the consensus analysts' recommendation for PLx Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PLx Pharma.

Has PLx Pharma been receiving favorable news coverage?

Media stories about PLXP stock have been trending negative on Saturday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PLx Pharma earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for PLx Pharma.

Who are some of PLx Pharma's key competitors?

What other stocks do shareholders of PLx Pharma own?

Who are PLx Pharma's key executives?

PLx Pharma's management team includes the folowing people:
  • Mr. Michael J. Valentino, Exec. Chairman (Age 65)
  • Ms. Natasha Giordano, CEO, Pres & Director (Age 59)
  • Mr. Gary L. Mossman, Sr. Advisor (Age 78)
  • Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 66)
  • Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 51)

When did PLx Pharma IPO?

(PLXP) raised $68 million in an initial public offering on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

Who are PLx Pharma's major shareholders?

PLx Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include University of Texas Texas AM Investment Managment Co. (0.68%). Company insiders that own PLx Pharma stock include Michael J Valentino and Park West Asset Management Llc. View Institutional Ownership Trends for PLx Pharma.

Which major investors are buying PLx Pharma stock?

PLXP stock was acquired by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co.. Company insiders that have bought PLx Pharma stock in the last two years include Michael J Valentino and Park West Asset Management Llc. View Insider Buying and Selling for PLx Pharma.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $5.63.

How big of a company is PLx Pharma?

PLx Pharma has a market capitalization of $51.51 million and generates $750,000.00 in revenue each year. The biotechnology company earns $900,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. PLx Pharma employs 12 workers across the globe.View Additional Information About PLx Pharma.

What is PLx Pharma's official website?

The official website for PLx Pharma is http://www.plxpharma.com/.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]

MarketBeat Community Rating for PLx Pharma (NASDAQ PLXP)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  385
MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel